Abstract
Numerous studies report the relationship between aspirin and other nonsteroidal anti-inflammatories (NSAIDs) and cancer incidence, in particular for colorectal cancer. This paper systematically reviews the evidence of the effect of aspirin and other NSAIDs on the primary prevention of colorectal and other gastrointestinal cancers in the general population.
In 25 investigations of NSAIDs and colorectal cancer, 23 observational studies reported a relative risk reduction but estimates vary widely. Cohort studies generally indicate lesser reductions than case-control studies suggesting possible biases in the latter. Clear evidence of a dose relationship generally appears lacking but data do not indicate useful effects of aspirin in cardioprophylactic doses. Differences have otherwise not been detected between aspirin and other NSAIDs, nor between non-aspirin NSAIDs. There is some evidence that the risk of colorectal cancer reduces with increased duration of NSAID use. The lower incidence of oesophageal and gastric cancers results in smaller numbers of cases in the studies reporting these cancers, particularly in the cohort studies. The trend is for a risk reduction for oesophageal and gastric cancers in people taking NSAIDs, which is more likely to be statistically significant in the case-control studies. A very small number of observational studies have reported the relationship between NSAIDs and the incidence of pancreatic, gallbladder and liver cancers. These show no consistent relationship.
In view of the inadequate information about optimal dose and duration of NSAIDs for colorectal cancer reduction, and the adverse effects of NSAIDs, we are not yet in a position to recommend NSAIDs for the primary prevention of colorectal cancer in the general population.
Similar content being viewed by others
References
Office of National Statistics. Cancer trends in England and Wales 1950–1999. London: The Stationary Office, 2001
Winawer SJ, Zauber AG, O’Brien MJ, et al. Randomised comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993; 328: 901–6
Cairns A, Quirke P. Flat adenomas. Br J Surg 1999; 86: 1489–90
World Health Organization. IARC Handbook of Cancer Prevention. Non-steroidal anti-inflammatory drugs. Vol 1. Paris: International Agency for Research on Cancer, 1997
Arber N. Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 2000; 14: 299–307
NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD Report Number 4. 2nd ed. York: University of York, 2001
Isomaki HA, Hakulinen T, Kannan K. Excess risk of lymphoma, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691–6
Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11
Paganini-Hill A. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299: 1247–50
Paganini-Hill A, Hsu G, Ross RK, et al. Aspirin use and incidence of large bowel cancer in a California retirement. J Natl Cancer Inst 1991; 83: 1182–3
Paganini-Hill A. Aspirin and colorectal cancer: the Leisure World Cohort revisited. Prev Med 1995; 24: 113–5
Thun MJ. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–7
Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138–46
Giovannucci E, Rimm EG, Stampfer KM, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–6
Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–14
Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996; 14: 551–3
Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 1580–6
Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 1999; 159: 161–6
Bucher C, Jordan P, Nickeleit V, et al. Relative risk of malignant tumors in analgesic abusers: effects of long-term intake of aspirin. Clin Nephrol 1999; 51: 67–72
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399–404
Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355–8
Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171–7
Peleg I, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394–9
Muscat JE, Stellman SD, Wynder EL. Non-steroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847–54
Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: a case-control study among veterans. Dig Dis Sci 1994; 39: 2480–4
Reeves MJ, Newcombe PA, Trentham-Dietz A, et al. Non-steroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996; 5: 955–60
Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44–8
Peleg II, Lubin MF, Cotsonis GA, et al. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41: 1319–6
La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997; 76: 675–7
Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel cancer. Cancer 1998; 83: 2326–33
Collett JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81: 62–8
Langman MJS, Cheng KK, Gilman A, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642–6
Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin non-steroidal antiinflammatory drugs. Epidemiology 2001; 12: 88–93
Gann PH, Manson JE, Glunn RJ, et al. Low dose aspirin and incidence of colorectal tumors in randomised trial. J Natl Cancer Inst 1993; 85: 1220–4
Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med 1998; 128: 713–20
Funkhauser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116–9
Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97–102
Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9: 119–23
Zaridze D, Borisova E, Maximovitch D, et al. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999; 82: 473–6
Akre K, Ekstrom AM, Signorello LB, et al. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84(7): 965–8
Garidou A, Tzonou A, Lipworth L, et al. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996; 68: 295–9
Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal ademonas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993; 307: 285–9
Martinez ME, McPherson RS, Levin B, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995; 4: 703–7
Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prosanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58: 1750–3
Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methyloxymethanol-induced large bowel tumors in rats. Gann 1980; 71: 260–4
Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996; 17: 1757–60
Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556–60
Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710–4
Schiff SJ, Rigas B. Non-steroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992–8
Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulphide and sulphone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110–6
Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57: 2452–9
Li M, Lotan R, Levin B, et al. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 545–9
Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 4356–62
Morgan G, Vainio H. Barrett’s oesophagus, oesophageal cancer and colon cancer; an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs. Eur J Cancer Prev 1998; 7: 195–9
Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome-c dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93: 218–23
Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenosis polyposis. Gastroenterology 1991; 101: 635–9
Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenosis polyposis. N Engl J Med 1993; 328: 1313–6
Acknowledgements
Professor Langman has acted as a consultant for Merck Sharp and Dohme. Any payment received goes to the University of Birmingham.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jolly, K., Cheng, K.K. & Langman, M.J.S. NSAIDs and Gastrointestinal Cancer Prevention. Drugs 62, 945–956 (2002). https://doi.org/10.2165/00003495-200262060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262060-00006